Previous studies have shown that administering exogenous Ang II to patients with distributive shock and severe AKI is associated with better survival rates and a reduced need for renal replacement therapy, likely due to the reduction in vasodilatory angiotensin levels [3,27]. This evidence concerns the gene AGT and acute kidney injury.